Notification That Form 20-f Will Be Submitted Late (nt 20-f)
May 01 2019 - 5:44AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 12b-25
NOTIFICATION OF LATE FILING
Commission File Number: 333-38041
CUSIP Number: 88339A203
(Check one):
o
Form 10-K
x
Form 20-F
o
Form 11-K
o
Form 10-Q
o
Form 10-D
o
Form N-SAR
o
Form N-CSR
For Period Ended: December 31, 2018
o
Transition Report on Form 10-K
o
Transition Report on Form 20-F
o
Transition Report on Form 11-K
o
Transition Report on Form 10-Q
o
Transition Report on Form N-SAR
For the Transition Period Ended:
NOTHING IN THIS FORM SHALL BE CONSTRUED TO IMPLY THAT THE COMMISSION
HAS VERIFIED ANY INFORMATION CONTAINED HEREIN.
If the notification relates to a portion of the filing checked above,
identify the Item(s) to which the notification relates:
PART I
REGISTRANT INFORMATION
Therapix Biosciences Ltd.
Full Name of Registrant
Former Name if Applicable
4
Ariel Sharon Street, HaShahar Tower, 16th Floor
Address of Principal Executive Office (
Street
and Number
)
Givatayim,
Israel, 5320047
City, State and Zip Code
PART II
RULE 12b-25(b) AND (c)
If the subject report could not be filed without unreasonable effort
or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate.)
|
(a) The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
|
x
|
(b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
|
|
(c) The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.
|
PART III
NARRATIVE
State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q,
10-D, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.
Therapix Biosciences Ltd. (the “Company”) is filing
this Notification of Late Filing on Form 12b-25 (the “Form 12b-25”) with respect to its Annual Report on Form 20-F
for the fiscal year ended December 31, 2018 (the “Annual Report”). The Company has determined that it is unable to
file the Annual Report by the prescribed due date of April 30, 2019, without unreasonable effort or expense. As a result of the
Company’s investment in Therapix Healthcare Resources Inc. on July 26, 2018, the Company has experienced unexpected
delays in
obtaining and compiling financial information and other data that is necessary
in
its preparation of its financial statements for the year ended December 31, 2018. The Company expects to file the Annual
Report on or before May 15, 2019.
PART IV
OTHER INFORMATION
(1) Name and telephone number of person to contact in regard to
this notification
Oz Adler +972-3-6167055
(Name) (Area Code) (Telephone Number)
(2) Have all other periodic reports required under Section 13 or
15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months
or for such shorter period that the registrant was required to file such report(s) been filed? If the answer is no, identify report(s).
Yes
x
No
o
(3) Is it anticipated that any significant change in results of
operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in
the subject report or portion thereof?
Yes
o
No
x
If so: attach an explanation of the anticipated change, both narratively
and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.
Therapix Biosciences Ltd.
(Name of Registrant as Specified in Charter)
has caused this notification to be signed on its behalf by the undersigned
hereunto duly authorized.
Date: May 1, 2019
|
By:
|
/s/ Oz Adler
|
|
|
|
Oz Adler
|
|
|
|
Chief Financial Officer
|
|
INSTRUCTION: The form may be signed by an executive officer of the
registrant or by any other duly authorized representative. The name and title of the person signing the form shall be typed or
printed beneath the signature. If the statement is signed on behalf of the registrant by an authorized representative (other than
an executive officer), evidence of the representative’s authority to sign on behalf of the registrant shall be filed with
the form.
ATTENTION
INTENTIONAL MISSTATEMENTS OR OMISSIONS OF FACT CONSTITUTE FEDERAL
CRIMINAL VIOLATIONS (SEE 18 U.S.C. 1001).
Therapix Biosciences (NASDAQ:TRPX)
Historical Stock Chart
From Apr 2024 to May 2024
Therapix Biosciences (NASDAQ:TRPX)
Historical Stock Chart
From May 2023 to May 2024